Neuren Pharmaceuticals Limited (NURPF PINK) stock market data APIs
$8.7584
0(0%)
as of July 2, 2025
Try our APIs with
free plan!
Neuren Pharmaceuticals Limited Financial Data Overview
Price chart is built with
Anychart
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.
Prev. Close
8.7584
Open
8.7584
High
8.7584
Low
8.7584
52 wk Range
6.6-14.25
Market Cap
1 161 M
P/E Ratio
12.4085
Shares Outstanding
126 M
Revenue
217 M
EPS
-0.0261
Beta
1.733
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neuren Pharmaceuticals Limited data using free add-ons & libraries
Get Neuren Pharmaceuticals Limited Fundamental Data
Neuren Pharmaceuticals Limited Fundamental data includes:
- Net Revenue: 217 M
- EBITDA: 179 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuren Pharmaceuticals Limited News
New
Exploring 3 Undervalued Small Caps With Insider Buying In Global Markets
In recent weeks, global markets have experienced mixed performance, with smaller-cap indexes like the S&P MidCap 400 and Russell 2000 showing gains despite broader market challenges. Economic uncertai...
Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
Neuren Pharmaceuticals (ASX:NEU) Full Year 2024 Results Key Financial Results Revenue: AU$216.8m (down 6.5% from FY 2023). Net income: AU$142.0m (down 9.6% from FY 2023). Profit margin: 66% (down fr...
News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat
The analysts covering Neuren Pharmaceuticals Limited (ASX:NEU) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both r...
Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Just think about the savvy inves...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
